Abstract | BACKGROUND AND PURPOSE: METHODS: Consecutive patients treated with IAT from December 1992 to October 2010 were included. Clinical outcome and mortality were assessed 90 days after stroke onset. Patients with and without previous use of OAC were compared. RESULTS: Overall, 714 patients were treated with IAT. Twenty-eight patients (3.9%) were under OAC at time of symptom onset. Median INR in the OAC group was 1.79 (interquartile range [IQR], 1.41-2.3) and 1.01 (IQR, 1.0-1.09; P<0.0001) in the group without OAC. Patients treated with OAC at admission underwent more often mechanical-only IAT than did patients without OAC (46.4% versus 12.8%; P<0.0001). Comparing patients with and without previous use of OAC, we did not find any statistical difference in the rate of symptomatic intracranial hemorrhage (7.1% versus 6.0%; P=0.80), unfavorable outcome (modified Rankin Scale score, 3-6; 67.9% versus 50.9%; P=0.11), and mortality (17.9% versus 21.6%; P=0.58). CONCLUSIONS: Previous use of OAC did not significantly increase the risk of symptomatic intracranial hemorrhage after IAT or the risk of unfavorable outcome and mortality 90 days after IAT.
|
Authors | Gian Marco De Marchis, Simon Jung, Giuseppe Colucci, Niklaus Meier, Urs Fischer, Anja Weck, Marie-Luise Mono, Aekaterini Galimanis, Heinrich P Mattle, Gerhard Schroth, Jan Gralla, Marcel Arnold, Caspar Brekenfeld |
Journal | Stroke
(Stroke)
Vol. 42
Issue 11
Pg. 3061-6
(Nov 2011)
ISSN: 1524-4628 [Electronic] United States |
PMID | 21980194
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Anticoagulants
- Tissue Plasminogen Activator
|
Topics |
- Administration, Oral
- Aged
- Anticoagulants
(administration & dosage)
- Brain Ischemia
(drug therapy, mortality)
- Cohort Studies
- Female
- Humans
- Infusions, Intra-Arterial
- Intracranial Hemorrhages
(drug therapy, mortality)
- Male
- Middle Aged
- Retrospective Studies
- Stroke
(drug therapy, mortality)
- Thrombolytic Therapy
(methods)
- Tissue Plasminogen Activator
(administration & dosage)
- Treatment Outcome
|